Objective-To investigate the feasibility of coronary stenting in acute myocardial infarction. Design-Prospective observational study. Patients-80 patients undergoing direct balloon angioplasty for acute myocardial infarction who had coronary PalmazSchatz stents implanted during a 3 year study period. Indications for stenting were abrupt reocclusion, large dissection with threatened reocclusion, and failure to achieve brisk flow of contrast by angioplasty alone. Interventions-After stenting, 50 patients were treated by conventional anticoagulation and 30 patients received antiplatelet therapy with aspirin and ticlopidine. Main outcome measures-Death and subacute reocclusion within two weeks.
Objective-To investigate the feasibility of coronary stenting in acute myocardial infarction. Design-Prospective observational study. Patients-80 patients undergoing direct balloon angioplasty for acute myocardial infarction who had coronary PalmazSchatz stents implanted during a 3 year study period. Indications for stenting were abrupt reocclusion, large dissection with threatened reocclusion, and failure to achieve brisk flow of contrast by angioplasty alone. Failure to achieve reperfusion is rare with this approach but it carries a high mortality (31%-43%)7-9 that reaches 78% when combined with cardiogenic shock.2 Moreover, reocclusion occurs in 10%-15% of the patients after successful direct PTCA. 10 12 Though reocclusion is often asymptomatic, 10 12 it abrogates most of the benefit from timely reperfusion.3 8 10 Previous studies suggest that the risk of reocclusion is particularly high when coronary blood flow continues to be compromised after recanalisation" 14 For dosages refer to the methods section.
weeks. Eight patients who had contraindications to phenprocoumon or were potential candidates for emergency cardiac surgery were treated by full dose heparin and aspirin only. Because of the favourable experience with antiplatelet therapy alone,333536 from May 1994 onwards 30 patients received 2 x 250 mg ticlopidine plus 2 x 100 mg aspirin instead of conventional anticoagulation.
FOLLOW-UP AND OUTCOME MEASURES
Patients remained in hospital for at least 14 days. Eight weeks and six months after discharge they were reassessed to monitor subsequent events. All surviving patients were scheduled for repeat coronary angiography, which was performed before discharge or at subsequent follow up visits. Six months clinical follow up was complete for all patients except one who presented in Killip class II and was lost to follow up after being discharged from hospital on day 15.
Outcome measures were angiographic procedural success, angiographic evidence of reocclusion of the stented segment, reinfarction, and cardiac death. Angiographic procedural success was defined by TIMI grade 3 flow with reduction of diameter stenosis to less than 50%, and reinfarction was defined as recurrent chest pain lasting more than 30 
In hospital: Cardiac death (n (%)) 3 (4-5) 4 (28 6) Non-lethal reinfarction (n (%)) 1 (1-5) In all of the 14 patients presenting with Killip class IV, stenting was primarily successful (table 2) . The main indication for stenting was failure to maintain TIMI grade 3 flow by PTCA alone (table 2) . Patient survival and major events are shown in fig 1 and table 4 . Four in-hospital deaths occurred. One patient died within the catheterisation laboratory because of electromechanical uncoupling despite an open stent, one patient did not survive emergency cardiac surgery for papillary muscle rupture, and two patients died of progressive heart failure-one had had a reinfarction. Within six months after the intervention, three additional deaths occurred out of hospital because of progressive heart failure (n = 2) and sudden death. In the seven surviving patients, major clinical events, such as reinfarction or coronary bypass surgery, were not encountered. We obtained angiographic follow up in six of the surviving patients at a median of 19 days (interquartile range 16-27 days) after the intervention, which revealed a patent stent in each case.
ROLE OF THROMBUS IMMEDIATELY BEFORE
STENT DELIVERY AND OF ANTITHROMBOTIC REGIMEN Among patients with repeat angiography, stent implantation in the presence of visible thrombus was associated with a reocclusion rate of 3/25 versus 2/40 in the absence of thrombus (P = 0 58). Major clinical events were encountered in 5/29 patients with visible thrombus immediately before stent delivery and in 6/51 of those without (P = 0 73).
Stent thromboses did not occur in patients on antiplatelet therapy with ticlopidine. Moreover, all patients treated with ticlopidine survived the in-hospital period, and only one of these patients died (94 days) after the intervention. Among major complications, two surgical vascular repairs and one transfusion were required in 50 anticoagulated patients, while in 30 patients treated with ticlopidine one bleeding required transfusion (P = 099). Cerebrovascular accident was not encountered in either group.
Discussion
The study is the first to report extensive clinical experience with intracoronary stents in patients with acute myocardial infarction. It demonstrates that implantation of an intracoronary stent is safe and effective in optimising coronary artery patency after complicated PTCA. Intracoronary stenting fully restored coronary flow across the recanalised vessel in all but one patient (98-8%) with reduced coronary blood flow, acute reocclusion, or large dissection with threatened reocclusion. Thus the primary technical success rate of stenting in acute myocardial infarction was similar to that in elective stenting.38 Contrary to common conjecture, the benefit from coronary stenting was not negated by abundant reocclusions.
OUTCOME IN PATIENTS WITH SYMPTOMS OF KILLIP CLASSES I TO III
In patients with symptoms of Killip classes I to III, repeat angiography at a rate of 89-4% revealed an occluded stent in 8-5% of the patients. Even though our patients were selected for a high risk of vessel closure, this reocclusion rate was lower than in mixed populations undergoing direct PTCA for acute myocardial infarction. [10] [11] [12] Moreover, the reocclusion rate after coronary stenting in acute myocardial infarction was within the published range of 6-9% to 17% for the rate of subacute thrombosis after bail-out stenting in elective PTCA.'8 19 34 The clinical outcome of coronary stenting in acute myocardial infarction corresponds to the favourable angiographic results. After one month, the combined rate of reinfarction and death after stenting in patients with symptoms of Killip class I to III was 6 1%. This event rate contrasts to the known poor prognosis of failed direct PTCA.7-9 It is close to the range of 3 4% to 5 1% for the rate of death and reinfarction reported in recent controlled trials on direct PTCA in acute myocardial infarction.4-6 OUTCOME IN PATIENTS WITH SYMPTOMS OF
KILLIP CLASS IV
The study suggests that the benefit from coronary stenting after failed direct PTCA may be even larger in patients with cardiogenic shock. Using coronary stents, we achieved complete coronary artery patency in all of our 14 patients with Killip class IV symptoms, despite the initial failure of direct PTCA, and 10 of them could be discharged from hospital alive. Analysis of the rate of chronic restenosis, however, was beyond the scope of the present study.
CLINICAL PERSPECTIVES
Failure of direct PTCA in acute myocardial infarction represents a serious therapeutic dilemma.7-9 Among the approaches that have been pursued in this situation, emergency coronary bypass surgery carries a high risk for the patient'9 and imposes an enormous logistic burden on the institution. Prolonged intracoronary thrombolysis, on the other hand, is of limited efficacy,40 since it usually cannot abolish the underlying pathology, such as dissection, and may substantially increase the risk of bleeding and access site complications.
The present study establishes that coronary stenting is a treatment option for suboptimal results of direct PTCA that is both safe and efficacious. The precise indication for coronary stenting as an adjunct to direct PTCA and the optimal adjuvant antithrombotic therapy remain to be determined. At present, however, the coronary stent may be regarded as a useful tool to restore coronary patency after complicated direct PTCA, provided the institutional expertise and the target vessel anatomy allow safe implantation.
